MYC-053

TGV-therapeutics is focused on the development of MYC-053, a novel and structurally distinct antifungal antibiotic, to treat various multidrug-resistant fungal infections.

MYC-053 represents a new chemical class of antifungal agents. It is not related to any of the three existing classes of antifungal agents, whose use is frequently characterized by cross-resistance.

MYC-053 possesses a unique dual mode of action against pathogenic fungi. It is designed to simultaneously inhibit chitin synthasesynthesis, which produces chitin, an essential component of the fungal cell wall, and nucleic acid synthesis in fungi.

MYC-053, a lead clinical candidate, is developed as an oral agent for the treatment of different fungal infections, including life-threatening invasive fungal infections caused by Candida glabrataCandida aurisCryptococcus spp., and Pneumocystis spp.

MYC-053 targets
MYC-053 inhibits chitin synthase
MYC-053 inhibits chitin synthase
MYC-053 inhibits nucleic acid synthesis in fungi
MYC-053 inhibits nucleic acid synthesis in fungi